109 related articles for article (PubMed ID: 8000302)
1. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
2. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
4. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga AG; Pasquetti W; Robertson C; Decensi A
Cancer Detect Prev; 2000; 24(4):369-75. PubMed ID: 11059568
[TBL] [Abstract][Full Text] [Related]
5. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.
Decensi A; Torrisi R; Polizzi A; Gesi R; Brezzo V; Rolando M; Rondanina G; Orengo MA; Formelli F; Costa A
J Natl Cancer Inst; 1994 Jan; 86(2):105-10. PubMed ID: 8271292
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
7. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
[TBL] [Abstract][Full Text] [Related]
8. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
9. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
10. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
Formelli F; Clerici M; Campa T; Di Mauro MG; Magni A; Mascotti G; Moglia D; De Palo G; Costa A; Veronesi U
J Clin Oncol; 1993 Oct; 11(10):2036-42. PubMed ID: 8410127
[TBL] [Abstract][Full Text] [Related]
11. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
13. Effects of fenretinide (4-HPR) on dark adaptation.
Caruso RC; Zujewski J; Iwata F; Podgor MJ; Conley BA; Ayres LM; Kaiser-Kupfer MI
Arch Ophthalmol; 1998 Jun; 116(6):759-63. PubMed ID: 9639444
[TBL] [Abstract][Full Text] [Related]
14. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
15. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
16. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
Decensi A; Formelli F; Torrisi R; Costa A
J Cell Biochem Suppl; 1993; 17G():226-33. PubMed ID: 8007703
[TBL] [Abstract][Full Text] [Related]
18. Plasma retinol and prognosis of postmenopausal breast cancer patients.
Formelli F; Meneghini E; Cavadini E; Camerini T; Di Mauro MG; De Palo G; Veronesi U; Berrino F; Micheli A
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):42-8. PubMed ID: 19124479
[TBL] [Abstract][Full Text] [Related]
19. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
[TBL] [Abstract][Full Text] [Related]
20. Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Dimitrov NV; Meyer CJ; Perloff M; Ruppenthal MM; Phillipich MJ; Gilliland D; Malone W; Minn FL
Am J Clin Nutr; 1990 Jun; 51(6):1082-7. PubMed ID: 2140925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]